By Victoria Masterson
A SPIN-OUT from the University of Edinburgh has raised £1 million to develop a new device that could “revolutionise” the early diagnosis and monitoring of difficult to detect cancers, such as kidney, thyroid and brain cancer.
BioCaptiva raised the seed investment from business angel syndicate, Archangels, and economic development agency Scottish Enterprise for its ‘BioCollector’ device.
The company says this overcomes “significant limitations” of current liquid biopsy testing – where blood is analysed for cells from cancerous tumours.
“We are confident that this platform technology can make a significant impact in this important area and, ultimately, enable cancers to be detected more quickly and accurately, enabling patients to receive precision cancer treatment as early as possible,” said BioCaptiva chief executive Jeremy Wheeler.